The relative importance of NADPH:: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions

被引:38
作者
Saunders, MP
Jaffar, M
Patterson, AV
Nolan, J
Naylor, MA
Phillips, RM
Harris, AL
Stratford, IJ
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] Mt Vernon Hosp, Gray Lab, Canc Res Trust, Northwood HA6 2JR, Middx, England
[3] Univ Bradford, Clin Oncol Unit, Bradford BD7 1DP, W Yorkshire, England
[4] John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England
基金
英国医学研究理事会;
关键词
cytochrome P450 reductase; indolequinone bioreductive drugs; EO9; transfected P450R;
D O I
10.1016/S0006-2952(99)00405-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Analogues of EO9 (3-hydroxymethyl-5 -aziridinyl-1 -methyl-2[1H -indole-4-7-dione]prop-2-en-1-1-ol) which lack functionality at either the C-2 or C-3 position were synthesised. The aim was to establish the importance of each group towards toxicity and to give an indication as to whether substitution at either posit-ion altered activation and toxicity after metabolism by cellular NADPH: cytochrome c (P450) reductase (P450R). MDA231 breast cancer cells were transfected with the cDNA for human P450R and stable clones were isolated. These high P450R-expressing clones were used to determine the aerobic and hypoxic toxicity of EO9 and the two analogues that lacked functionality at either C-2 or C-3. The results showed that P450R was strongly implicated in the bioactivation of EO9 and its analogues under both of these conditions. This data also showed that the C-3 functionality was primarily implicated in hypoxic toxicity. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:993 / 996
页数:4
相关论文
共 16 条
[1]   STRUCTURE-ACTIVITY-RELATIONSHIPS FOR DT-DIAPHORASE REDUCTION OF HYPOXIC CELL DIRECTED AGENTS - INDOLOQUINONES AND DIAZIRIDINYL BENZOQUINONES [J].
BAILEY, SM ;
SUGGETT, N ;
WALTON, MI ;
WORKMAN, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (04) :649-653
[2]  
BAILEY SM, 1994, P AM ASSOC CANC RES, V25, P384
[3]  
BAILEY SM, 1994, BR J CANCER S21, V69, P57
[4]   CYCLOPROPAMITOSENES, NOVEL BIOREDUCTIVE ANTICANCER AGENTS - SYNTHESIS, ELECTROCHEMISTRY, AND BIOLOGICAL-ACTIVITY OF 7-SUBSTITUTED CYCLOPROPAMITOSENES AND RELATED INDOLEQUINONES [J].
COTTERILL, AS ;
MOODY, CJ ;
MORTIMER, RJ ;
NORTON, CL ;
OSULLIVAN, N ;
STEPHENS, MA ;
STRADIOTTO, NR ;
SWANN, E ;
STRATFORD, IJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (22) :3834-3843
[5]  
Franck R. W., 1990, CHEM ANTITUMOR AGENT, P379
[6]   Hypoxia and radiation response in human tumors [J].
Hockel, M ;
Schlenger, K ;
Mitze, M ;
Schaffer, U ;
Vaupel, P .
SEMINARS IN RADIATION ONCOLOGY, 1996, 6 (01) :3-9
[7]  
Jaffar M, 1998, ANTI-CANCER DRUG DES, V13, P105
[8]  
Jaffar M, 1998, ANTI-CANCER DRUG DES, V13, P593
[9]   2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: Structure-activity in vitro and efficacy in vivo [J].
Naylor, MA ;
Jaffar, M ;
Nolan, J ;
Stephens, MA ;
Butler, S ;
Patel, KB ;
Everett, SA ;
Adams, GE ;
Stratford, IJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (15) :2335-2346
[10]   MITOMYCIN ANALOGS .1. INDOLOQUINONES AS (POTENTIAL) BISALKYLATING AGENTS [J].
OOSTVEEN, EA ;
SPECKAMP, WN .
TETRAHEDRON, 1987, 43 (01) :255-262